ZOLOFT ® (sertraline, as hydrochloride) VIATRIS HK Reg. No. HK-68926 (09 Dec, 2025) Composition: 3 ZOLOFT ® is available in 100 mg tablets, along with other dosage forms Indication: 3 ZOLOFT ® is a selective serotonin reuptake inhibitor ...
Children diagnosed with ADHD, particularly those receiving long-term methylphenidate treatment, demonstrated higher body mass index (BMI) and reduced height at adulthood compared to individuals without ADHD. This matched cohort study examined growth...
Among 2,800 help-seekers for gambling-related problems in Finland, women demonstrated significantly higher rates of suicidal ideation compared to men (25.5% versus 16.4%), with gambling-related debts and inadequate social support identified as criti...
New research suggests that auditory hallucinations in schizophrenia may occur when the brain fails to recognize its own “inner speech”, the silent voice most people use to think. Researchers compared EEG recordings between schizophrenic ...
DESPAXOR ® (desvenlafaxine, as succinate) SYNCO HK Reg. No. HK-68803, HK-68804 (07 Aug, 2025) Composition: 1 • DESPAXOR is available in the following dosage forms: 50 mg and 100 mg extended-release oral tablets • Each tablet contains 7...
The disease burden of mental disorders has become increasingly relevant as this causes a high degree of individual and social suffering, whereas mood and anxiety disorders are commonly involved. Previous pooled analysis suggested that the lifetime p...
Clozapine is the only approved treatment for patients with treatment-resistant schizophrenia (TRS) but response rates remain at 50 – 60% 1 . Evenamide, a sodium channel blocker, has shown efficacy in a phase II trial to significantly reduce sy...
Anxiety disorders are one of the most prevalent psychiatric disorders, up to 30% of the population are reported to be affected by an anxiety disorder during their lifetime. While anxiety disorders are associated with a significant disease burden and...
LEQEMBI® (lecanemab) EISAI HK Reg. No. HK-68289 (03 Jul, 2024) & HK-68290 (03 Jul, 2024) Composition: 3 LEQEMBI® is an amyloid beta-directed antibody with the active ingredient lecanemab-irmb. It is administered as an intravenous infusio...
Major depressive disorder (MDD) is highly prevalent and affects more than 264 million individuals, globally. Remarkably, despite treatment, up to half of the patients with depression fail to reach remission and are at risk of experiencing treatment-...
Schizophrenia is a psychiatric syndrome of delusions, disorganised speech, hallucinations, and impaired executive functioning1. Despite affecting approximately 1% of the global population, poor treatment adherence remains as an unmet need associated...
